Literature DB >> 1608849

Population pharmacokinetics of gentamicin in neonates using a nonlinear, mixed-effects model.

P D Jensen1, B E Edgren, R C Brundage.   

Abstract

The population pharmacokinetics of gentamicin in neonates was determined using a nonlinear, mixed-effects model (NONMEM). The final regression equations derived to estimate clearance (Cl) and volume of distribution (Vd) were Cl = 0.120 * (WT/2.4)1.36 L/hr and Vd = 0.429 * (WT) L. The interindividual variability (% CV) for clearance was 26.2% and for volume of distribution 15.9%. Intraindividual variability was 11.0%. In a separate group of 30 neonates, the predictive ability of the NONMEM-generated population variables was compared to the predictions from a standard two-stage population analysis. The trough concentrations predicted using NONMEM-generated parameters were significantly less biased and more precise; there were no significant differences between the methods in predicting peaks. NONMEM is a useful tool for determining population pharmacokinetics and appears to be consistent across populations using routine clinical data and limited observation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1608849

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  18 in total

Review 1.  Pharmacokinetic studies in infants using minimal-risk study designs.

Authors:  Julie Autmizguine; Daniel K Benjamin; P Brian Smith; Mario Sampson; Philippe Ovetchkine; Michael Cohen-Wolkowiez; Kevin M Watt
Journal:  Curr Clin Pharmacol       Date:  2014

2.  Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates.

Authors:  Aline Fuchs; Monia Guidi; Eric Giannoni; Dominique Werner; Thierry Buclin; Nicolas Widmer; Chantal Csajka
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

3.  Gentamicin pharmacokinetics in preterm infants with a patent and a closed ductus arteriosus.

Authors:  D J Touw; J H Proost; R Stevens; H N Lafeber; M M van Weissenbruch
Journal:  Pharm World Sci       Date:  2001-10

4.  Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis.

Authors:  J R Wade; S L Beal; N C Sambol
Journal:  J Pharmacokinet Biopharm       Date:  1994-04

5.  Population pharmacokinetics of intramuscular gentamicin administered to young infants with suspected severe sepsis in Kenya.

Authors:  Alison H Thomson; Gilbert O Kokwaro; Simon N Muchohi; Michael English; Shebbe Mohammed; Geoffrey Edwards
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

6.  Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study.

Authors:  Elisabet I Nielsen; Marie Sandström; Per Hartvig Honoré; Uwe Ewald; Lena E Friberg
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 7.  Therapeutic drug monitoring of aminoglycosides in neonates.

Authors:  Daniël J Touw; Elsbeth M Westerman; Arwen J Sprij
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

8.  Population pharmacokinetics of gentamicin in South African newborns.

Authors:  J H Botha; M J du Preez; M Adhikari
Journal:  Eur J Clin Pharmacol       Date:  2003-10-18       Impact factor: 2.953

Review 9.  Identification of populations at risk in drug testing and therapy: application to elderly patients.

Authors:  W A Ritschel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jan-Mar       Impact factor: 2.441

10.  Neural network predicted peak and trough gentamicin concentrations.

Authors:  M E Brier; J M Zurada; G R Aronoff
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.